Summary

Persistence Market Research has recently released an in-depth report on the Anti-VEGF Market, offering a detailed assessment of key market dynamics, including drivers, trends, opportunities, and challenges, providing thorough insights into the market structure.

Key Insights:

• Anti-VEGF Market Size (2024E): USD 23.8 Billion
• Projected Market Value (2033F): USD 35.1 Billion
• Global Market Growth Rate (CAGR 2024 to 2033): 4.4%

Scope of the Report: Anti-VEGF Market

Anti-VEGF therapies are crucial in treating various medical conditions, such as age-related macular degeneration (AMD), diabetic retinopathy, and certain cancers. These therapies target vascular endothelial growth factor (VEGF) to inhibit angiogenesis and manage disease progression effectively. The Anti-VEGF Market primarily serves hospitals, clinics, ophthalmology centers, and specialized treatment facilities, offering a range of treatment options, including intravitreal injections and oral medications.

Market Growth Drivers:

The global Anti-VEGF Market is propelled by several factors, including the rising prevalence of AMD and diabetic retinopathy worldwide, advancements in biotechnology that enhance drug efficacy and patient outcomes, and growing awareness among healthcare providers about the benefits of early intervention with Anti-VEGF therapies. Technological innovations in drug delivery systems and the expansion of telemedicine services further drive market growth by improving treatment accessibility and patient compliance.

Market Challenges:

Despite promising growth prospects, the Anti-VEGF Market faces challenges related to high treatment costs, regulatory complexities in drug approvals and market entry, and potential adverse effects associated with long-term therapy. Limited reimbursement coverage for Anti-VEGF treatments in certain regions also poses barriers to market expansion, particularly in emerging economies with constrained healthcare budgets.

Market Opportunities:

The Anti-VEGF Market presents significant growth opportunities driven by ongoing research and development initiatives focused on novel drug formulations, personalized medicine approaches, and combination therapies targeting multiple disease pathways. Strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers are crucial to accelerate innovation and address unmet medical needs in ophthalmology and oncology.

Key Questions Addressed in the Report:

• What are the primary factors driving the growth of the Anti-VEGF Market globally?
• Which therapeutic applications and patient populations are driving Anti-VEGF adoption across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the Anti-VEGF Market?
• Who are the key players contributing to the Anti-VEGF Market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global Anti-VEGF Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Anti-VEGF Market, including Roche Holding AG, Novartis AG, and Regeneron Pharmaceuticals, Inc., focus on innovation, strategic alliances, and regulatory compliance to maintain a competitive edge. These companies invest significantly in clinical trials, regulatory submissions, and post-marketing surveillance to ensure product safety and efficacy. Collaborations with ophthalmologists, oncologists, and patient advocacy groups facilitate market access and promote therapeutic advancements in Anti-VEGF therapy.

Key Companies Profiled:

• Pfizer Inc.
• Novartis AG
• Sanofi SA
• Bayer Healthcare LLC
• F. Hoffmann-La Roche Ltd.
• Amgen Inc.
• Eli Lilly and Company
• Eisai Co., Ltd.
• Sino Pharma
• Amneal Pharmaceuticals Inc.
• Exelixis, Inc.
• HUTCHMED

Key Segments of Anti-VEGF Industry Research

By Drug:
• Small Molecules
• Biologics

By Type:
• VEGF-A Inhibitors
• VEGF-B Inhibitors
• VEGF-C Inhibitors
• Placenta Growth Factor Inhibitors

By Disease Indication:
• Oncology
• Hematology Disorders
• Ophthalmology Disorders

By Distribution Channel:
• Hospitals
• Specialty Clinics
• Mail Order Pharmacies

Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Regulatory Landscape
4.2. Pipeline Assessment
4.3. Product Adoption and Usage Analysis
4.4. Key Marketing & Promotional Strategies Adopted by Companies
4.5. PESTLE Analysis
4.6. Porters Analysis
4.7. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Spending Outlook
5.1.3. Global Oncology Therapeutic Medicines Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increase in R&D Funding and Grants
5.2.2. Rising Research Activities for Rare Disease Indications
5.2.3. High Demand for Biologics
5.2.4. Surge in Research Collaborations for Development of Drugs
5.2.5. High Prevalence of Cancer
5.2.6. New Product Launch
5.2.7. Regulatory Approvals
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Drug Types
6.1.2. Revenue By Types
6.1.3. Revenue By Disease Indication
6.1.4. Revenue By Distribution Channel
6.1.5. Revenue By Country
6.2. 2024 Market Scenario
7. Global Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033
7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Types
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis, By Drug Types, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug Types, 2024-2033
8.3.1. Small Molecules
8.3.1.1. Pazopanib
8.3.1.2. Sunitinib
8.3.1.3. Regorafenib
8.3.1.4. Cabozantinib
8.3.1.5. Lenvatinib
8.3.1.6. Ponatinib
8.3.1.7. Cabozantinib
8.3.1.8. Axitinib
8.3.1.9. Tivozanib
8.3.1.10. Vandetanib
8.3.1.11. Sorafenib
8.3.1.12. Anlotinib
8.3.1.13. Apatinib
8.3.1.14. Fruquintinib
8.3.1.15. Surufatinib
8.3.2. Biologics
8.3.2.1. Bevacizumab
8.3.2.2. Ziv-Aflibercept
8.3.2.3. Ramucirumab
8.3.2.4. Ranibizumab
8.4. Market Attractiveness Analysis By Drug Types
9. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Types
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Types, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Types, 2024-2033
9.3.1. VEGF A Inhibitors
9.3.2. VEGF B Inhibitors
9.3.3. VEGF C Inhibitors
9.3.4. Placenta Growth Factor Inhibitors
9.4. Market Attractiveness Analysis By Types
10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Disease Indication
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Disease Indication, 2024-2033
10.3.1. Oncology
10.3.1.1. Cervical Cancer
10.3.1.2. Non-Small Cell Lung Cancer
10.3.1.3. Renal Cell Carcinoma
10.3.1.4. Soft Tissue Sarcoma
10.3.1.5. Colorectal Cancer
10.3.1.6. Liver Cancer
10.3.1.7. Others
10.3.2. Hematology Disorders
10.3.3. Ophthalmology Disorders
10.3.3.1. Wet Age-Related Macular Degeneration (AMD)
10.3.3.2. Diabetic Retinopathy
10.3.3.3. Others
10.4. Market Attractiveness Analysis By Disease Indication
11. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
11.3.1. Hospitals
11.3.2. Specialty Clinics
11.3.3. Cancer Research Centers
11.3.4. Mail Order Pharmacies
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2019-2023 and Forecast 2024-2033
13.1. Introduction
13.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Drug Types
13.3.3. By Types
13.3.4. By Disease Indication
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Types
13.4.3. By Types
13.4.4. By Disease Indication
13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. U.S. Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Drug Types
13.8.1.2.2. By Types
13.8.1.2.3. By Disease Indication
13.8.1.2.4. By Distribution Channel
13.8.2. Canada Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Drug Types
13.8.2.2.2. By Types
13.8.2.2.3. By Disease Indication
13.8.2.2.4. By Distribution Channel
14. Latin America Market Analysis 2019-2023 and Forecast 2024-2033
14.1. Introduction
14.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug Types
14.3.3. By Types
14.3.4. By Disease Indication
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Types
14.4.3. By Types
14.4.4. By Disease Indication
14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Mexico Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Drug Types
14.8.1.2.2. By Types
14.8.1.2.3. By Disease Indication
14.8.1.2.4. By Distribution Channel
14.8.2. Brazil Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Drug Types
14.8.2.2.2. By Types
14.8.2.2.3. By Disease Indication
14.8.2.2.4. By Distribution Channel
14.8.3. Argentina Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Drug Types
14.8.3.2.2. By Types
14.8.3.2.3. By Disease Indication
14.8.3.2.4. By Distribution Channel
15. Europe Market Analysis 2019-2023 and Forecast 2024-2033
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Nordic Countries
15.3.1.8. Russia
15.3.1.9. Rest of Europe
15.3.2. By Drug Types
15.3.3. By Types
15.3.4. By Disease Indication
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Types
15.4.3. By Types
15.4.4. By Disease Indication
15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Drug Types
15.8.1.2.2. By Types
15.8.1.2.3. By Disease Indication
15.8.1.2.4. By Distribution Channel
15.8.2. Italy Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Drug Types
15.8.2.2.2. By Types
15.8.2.2.3. By Disease Indication
15.8.2.2.4. By Distribution Channel
15.8.3. France Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Drug Types
15.8.3.2.2. By Types
15.8.3.2.3. By Disease Indication
15.8.3.2.4. By Distribution Channel
15.8.4. U.K. Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Drug Types
15.8.4.2.2. By Types
15.8.4.2.3. By Disease Indication
15.8.4.2.4. By Distribution Channel
15.8.5. Spain Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Drug Types
15.8.5.2.2. By Types
15.8.5.2.3. By Disease Indication
15.8.5.2.4. By Distribution Channel
15.8.6. BENELUX Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Drug Types
15.8.6.2.2. By Types
15.8.6.2.3. By Disease Indication
15.8.6.2.4. By Distribution Channel
15.8.7. Nordic Countries Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Drug Types
15.8.7.2.2. By Types
15.8.7.2.3. By Disease Indication
15.8.7.2.4. By Distribution Channel
15.8.8. Russia Market Analysis
15.8.8.1. Introduction
15.8.8.2. Market Analysis and Forecast by Market Taxonomy
15.8.8.2.1. By Drug Types
15.8.8.2.2. By Types
15.8.8.2.3. By Disease Indication
15.8.8.2.4. By Distribution Channel
16. East Asia Market Analysis 2019-2023 and Forecast 2024-2033
16.1. Introduction
16.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Drug Types
16.3.3. By Types
16.3.4. By Disease Indication
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Types
16.4.3. By Types
16.4.4. By Disease Indication
16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug Types
16.8.1.2.2. By Types
16.8.1.2.3. By Disease Indication
16.8.1.2.4. By Distribution Channel
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug Types
16.8.2.2.2. By Types
16.8.2.2.3. By Disease Indication
16.8.2.2.4. By Distribution Channel
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug Types
16.8.3.2.2. By Types
16.8.3.2.3. By Disease Indication
16.8.3.2.4. By Distribution Channel
17. South Asia Market Analysis 2019-2023 and Forecast 2024-2033
17.1. Introduction
17.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Drug Types
17.3.3. By Types
17.3.4. By Disease Indication
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Types
17.4.3. By Types
17.4.4. By Disease Indication
17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. India Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug Types
17.8.1.2.2. By Types
17.8.1.2.3. By Disease Indication
17.8.1.2.4. By Distribution Channel
17.8.2. Indonesia Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug Types
17.8.2.2.2. By Types
17.8.2.2.3. By Disease Indication
17.8.2.2.4. By Distribution Channel
17.8.3. Malaysia Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Drug Types
17.8.3.2.2. By Types
17.8.3.2.3. By Disease Indication
17.8.3.2.4. By Distribution Channel
17.8.4. Thailand Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Drug Types
17.8.4.2.2. By Types
17.8.4.2.3. By Disease Indication
17.8.4.2.4. By Distribution Channel
18. Oceania Market 2019-2023 and Forecast 2024-2033
18.1. Introduction
18.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Drug Types
18.3.3. By Types
18.3.4. By Disease Indication
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug Types
18.4.3. By Types
18.4.4. By Disease Indication
18.4.5. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Drug Types
18.8.1.2.2. By Types
18.8.1.2.3. By Disease Indication
18.8.1.2.4. By Distribution Channel
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Drug Types
18.8.2.2.2. By Types
18.8.2.2.3. By Disease Indication
18.8.2.2.4. By Distribution Channel
19. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033
19.1. Introduction
19.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
19.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Drug Types
19.3.3. By Types
19.3.4. By Disease Indication
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug Types
19.4.3. By Types
19.4.4. By Disease Indication
19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Drug Types
19.8.1.2.2. By Types
19.8.1.2.3. By Disease Indication
19.8.1.2.4. By Distribution Channel
19.8.2. Türkiye Anti-VEGF Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Drug Types
19.8.2.2.2. By Types
19.8.2.2.3. By Disease Indication
19.8.2.2.4. By Distribution Channel
19.8.3. South Africa Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Drug Types
19.8.3.2.2. By Types
19.8.3.2.3. By Disease Indication
19.8.3.2.4. By Distribution Channel
19.8.4. North Africa Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Drug Types
19.8.4.2.2. By Types
19.8.4.2.3. By Disease Indication
19.8.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Concentration
20.4. Market Presence Analysis
20.4.1. Regional Footprint Analysis
20.4.2. Channel Footprint Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Pfizer Inc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Sales Footprint
21.3.1.4. Key Financial
21.3.1.5. Key Developments
21.3.1.6. SWOT Analysis
21.3.1.7. Strategy Overview
21.3.1.7.1. Marketing Strategies
21.3.1.7.2. Channel Strategies
21.3.2. Bayer AG
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Sales Footprint
21.3.2.4. Key Financial
21.3.2.5. Key Developments
21.3.2.6. SWOT Analysis
21.3.2.7. Strategy Overview
21.3.2.7.1. Marketing Strategies
21.3.2.7.2. Channel Strategies
21.3.3. Novartis AG
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Sales Footprint
21.3.3.4. Key Financial
21.3.3.5. Key Developments
21.3.3.6. SWOT Analysis
21.3.3.7. Strategy Overview
21.3.3.7.1. Marketing Strategies
21.3.3.7.2. Channel Strategies
21.3.4. Sanofi SA
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Sales Footprint
21.3.4.4. Key Financial
21.3.4.5. Key Developments
21.3.4.6. SWOT Analysis
21.3.4.7. Strategy Overview
21.3.4.7.1. Marketing Strategies
21.3.4.7.2. Channel Strategies
21.3.5. Exelixis Inc.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Sales Footprint
21.3.5.4. Key Financial
21.3.5.5. Key Developments
21.3.5.6. SWOT Analysis
21.3.5.7. Strategy Overview
21.3.5.7.1. Marketing Strategies
21.3.5.7.2. Channel Strategies
21.3.6. Eisai Co. Ltd.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Sales Footprint
21.3.6.4. Key Financial
21.3.6.5. Key Developments
21.3.6.6. SWOT Analysis
21.3.6.7. Strategy Overview
21.3.6.7.1. Marketing Strategies
21.3.6.7.2. Channel Strategies
21.3.7. Amgen Inc.
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Sales Footprint
21.3.7.4. Key Financial
21.3.7.5. Key Developments
21.3.7.6. SWOT Analysis
21.3.7.7. Strategy Overview
21.3.7.7.1. Marketing Strategies
21.3.7.7.2. Channel Strategies
21.3.8. F. Hoffmann-La Roche Ltd.
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Sales Footprint
21.3.8.4. Key Financial
21.3.8.5. Key Developments
21.3.8.6. SWOT Analysis
21.3.8.7. Strategy Overview
21.3.8.7.1. Marketing Strategies
21.3.8.7.2. Channel Strategies
21.3.9. Eli Lilly and Company
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Sales Footprint
21.3.9.4. Key Financial
21.3.9.5. Key Developments
21.3.9.6. SWOT Analysis
21.3.9.7. Strategy Overview
21.3.9.7.1. Marketing Strategies
21.3.9.7.2. Channel Strategies
21.3.10. Amneal Pharmaceuticals Inc.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Sales Footprint
21.3.10.4. Key Financial
21.3.10.5. Key Developments
21.3.10.6. SWOT Analysis
21.3.10.7. Strategy Overview
21.3.10.7.1. Marketing Strategies
21.3.10.7.2. Channel Strategies
21.3.11. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Sales Footprint
21.3.11.4. Key Financial
21.3.11.5. Key Developments
21.3.11.6. SWOT Analysis
21.3.11.7. Strategy Overview
21.3.11.7.1. Marketing Strategies
21.3.11.7.2. Channel Strategies
21.3.12. Takeda Pharmaceutical Co. Ltd.
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. Sales Footprint
21.3.12.4. Key Financial
21.3.12.5. Key Developments
21.3.12.6. SWOT Analysis
21.3.12.7. Strategy Overview
21.3.12.7.1. Marketing Strategies
21.3.12.7.2. Channel Strategies
21.3.13. Sino Biopharma
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. Sales Footprint
21.3.13.4. Key Financial
21.3.13.5. Key Developments
21.3.13.6. SWOT Analysis
21.3.13.7. Strategy Overview
21.3.13.7.1. Marketing Strategies
21.3.13.7.2. Channel Strategies
21.3.14. HUTCHMED
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. Sales Footprint
21.3.14.4. Key Financial
21.3.14.5. Key Developments
21.3.14.6. SWOT Analysis
21.3.14.7. Strategy Overview
21.3.14.7.1. Marketing Strategies
21.3.14.7.2. Channel Strategies
22. Assumptions and Acronyms Used
23. Research Methodology